T
twoXAR
Improving Health Through Computation
About twoXAR
Aria Pharmaceuticals is a preclinical stage pharmaceutical company dedicated to discovering and developing novel small molecule therapies for patients suffering from complex and hard-to-treat diseases. The company operates in the pharmaceutical and biotechnology market, focusing on early-stage drug discovery and development. Aria Pharmaceuticals serves a diverse range of clients including healthcare providers, research institutions, and patients in need of new treatments. The business model revolves around extensive research and development, leading to the creation of proprietary small molecule drugs. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of successful drug candidates. The company has recently advanced its pipeline by filing six provisional patents with the United States Patent and Trademark Office for lead candidates in lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) research programs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Palo Alto, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 65.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Risk Management, Statistics
- Technology
- Artificial Intelligence, Hardware, Big Data, Deep Tech, Machine Learning, Nanotech
- Business model
- Manufacturing, SaaS
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BEquity / VC | Jul 2021 | $0 | — | Network VC | — |
| SERIES A✓Equity / VC | Mar 2018 | $10M | $40M | Andreessen Horowitz · Softbank Capital · SBVA · OS Fund | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for twoXAR is 540 monthly website visits, up 3.8% over the last three months. twoXAR's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
CLI Ventures
Andreessen Horowitz
Series A4 investors entered at this stage
SBVA
Softbank Capital
OS Fund
Network VC
Other known investors3 additional known investors
Stanford University
Future Planet Capital
StartX
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about twoXAR on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See twoXAR’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.